Gene Biotherapeutics, Inc. (CRXM)
USD 0.0
(9900.0%)
USD 0.0
(9900.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | -100.0% |
| 2020 | 1.26 Million USD | 50.8% |
| 2019 | 837 Thousand USD | -28.05% |
| 2018 | 1.16 Million USD | -45.29% |
| 2017 | 2.12 Million USD | -25.16% |
| 2016 | 2.84 Million USD | -8.8% |
| 2015 | 3.11 Million USD | -12.9% |
| 2014 | 3.57 Million USD | -48.52% |
| 2013 | 6.94 Million USD | -20.51% |
| 2012 | 8.73 Million USD | 17.8% |
| 2011 | 7.41 Million USD | 5.76% |
| 2010 | 7.01 Million USD | -23.41% |
| 2009 | 9.15 Million USD | -62.93% |
| 2008 | 24.7 Million USD | -5.13% |
| 2007 | 26.04 Million USD | 36.27% |
| 2006 | 19.11 Million USD | 241.98% |
| 2005 | 5.58 Million USD | 1496.51% |
| 2004 | 350.03 Thousand USD | -15.65% |
| 2003 | 414.97 Thousand USD | -91.53% |
| 2002 | 4.89 Million USD | 422.67% |
| 2001 | 937.31 Thousand USD | -44.07% |
| 2000 | 1.67 Million USD | 105.24% |
| 1999 | 816.59 Thousand USD | -91.09% |
| 1998 | 9.16 Million USD | 7.4% |
| 1997 | 8.52 Million USD | 59.49% |
| 1996 | 5.34 Million USD | -19.55% |
| 1995 | 6.64 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | -100.0% |
| 2020 Q1 | 152.88 Thousand USD | -13.97% |
| 2020 FY | 1.26 Million USD | 50.8% |
| 2020 Q3 | 388.69 Thousand USD | 60.18% |
| 2020 Q4 | 477.94 Thousand USD | 22.96% |
| 2020 Q2 | 242.65 Thousand USD | 58.72% |
| 2019 FY | 837 Thousand USD | -28.05% |
| 2019 Q1 | 242.97 Thousand USD | 0.0% |
| 2019 Q2 | 240.82 Thousand USD | -0.88% |
| 2019 Q3 | 175.49 Thousand USD | -27.13% |
| 2019 Q4 | 177.7 Thousand USD | 1.26% |
| 2018 FY | 1.16 Million USD | -45.29% |
| 2017 Q1 | 651.98 Thousand USD | -17.23% |
| 2017 FY | 2.12 Million USD | -25.16% |
| 2016 Q3 | 1.01 Million USD | 66.46% |
| 2016 Q1 | 424 Thousand USD | 137.59% |
| 2016 FY | 2.84 Million USD | -8.8% |
| 2016 Q4 | 787.71 Thousand USD | -22.46% |
| 2016 Q2 | 610.32 Thousand USD | 43.94% |
| 2015 Q4 | 178.46 Thousand USD | -85.0% |
| 2015 FY | 3.11 Million USD | -12.9% |
| 2015 Q1 | 608.25 Thousand USD | 24.81% |
| 2015 Q2 | 1.13 Million USD | 87.16% |
| 2015 Q3 | 1.18 Million USD | 4.52% |
| 2014 Q1 | 1.43 Million USD | 1087.15% |
| 2014 Q2 | 956.32 Thousand USD | -33.52% |
| 2014 FY | 3.57 Million USD | -48.52% |
| 2014 Q3 | 713.2 Thousand USD | -25.42% |
| 2014 Q4 | 487.33 Thousand USD | -31.67% |
| 2013 Q3 | 1.95 Million USD | -17.37% |
| 2013 FY | 6.94 Million USD | -20.51% |
| 2013 Q1 | 2.51 Million USD | 10.03% |
| 2013 Q2 | 2.36 Million USD | -5.9% |
| 2013 Q4 | 121.17 Thousand USD | -93.79% |
| 2012 Q4 | 2.28 Million USD | 20.21% |
| 2012 FY | 8.73 Million USD | 17.8% |
| 2012 Q3 | 1.89 Million USD | 0.75% |
| 2012 Q2 | 1.88 Million USD | -29.56% |
| 2012 Q1 | 2.67 Million USD | 40.62% |
| 2011 Q2 | 1.97 Million USD | 11.12% |
| 2011 Q1 | 1.77 Million USD | 2.24% |
| 2011 Q4 | 1.9 Million USD | 8.11% |
| 2011 FY | 7.41 Million USD | 5.76% |
| 2011 Q3 | 1.75 Million USD | -11.04% |
| 2010 Q3 | 1.82 Million USD | -7.66% |
| 2010 FY | 7.01 Million USD | -23.41% |
| 2010 Q1 | 1.48 Million USD | -18.21% |
| 2010 Q2 | 1.97 Million USD | 33.2% |
| 2010 Q4 | 1.74 Million USD | -4.42% |
| 2009 Q2 | 2.32 Million USD | -36.16% |
| 2009 Q3 | 2.48 Million USD | 6.73% |
| 2009 Q4 | 1.81 Million USD | -27.19% |
| 2009 Q1 | 3.64 Million USD | -24.84% |
| 2009 FY | 9.15 Million USD | -62.93% |
| 2008 FY | 24.7 Million USD | -5.13% |
| 2008 Q2 | 6.86 Million USD | -1.32% |
| 2008 Q3 | 6.03 Million USD | -12.12% |
| 2008 Q4 | 4.85 Million USD | -19.5% |
| 2008 Q1 | 6.95 Million USD | -3.29% |
| 2007 Q4 | 7.19 Million USD | 14.89% |
| 2007 Q3 | 6.26 Million USD | -5.16% |
| 2007 Q2 | 6.6 Million USD | 10.21% |
| 2007 FY | 26.04 Million USD | 36.27% |
| 2007 Q1 | 5.98 Million USD | -14.63% |
| 2006 FY | 19.11 Million USD | 241.98% |
| 2006 Q4 | 7.01 Million USD | 25.95% |
| 2006 Q3 | 5.57 Million USD | 47.93% |
| 2006 Q2 | 3.76 Million USD | 36.42% |
| 2006 Q1 | 2.76 Million USD | 0.0% |
| 2005 Q2 | 35.53 Thousand USD | 7.29% |
| 2005 FY | 5.58 Million USD | 1496.51% |
| 2005 Q3 | 114.12 Thousand USD | 221.19% |
| 2005 Q1 | 33.11 Thousand USD | -50.84% |
| 2004 Q3 | 79.33 Thousand USD | -6.76% |
| 2004 Q4 | 67.36 Thousand USD | -15.1% |
| 2004 Q2 | 85.08 Thousand USD | 4.01% |
| 2004 FY | 350.03 Thousand USD | -15.65% |
| 2004 Q1 | 81.8 Thousand USD | -21.18% |
| 2003 FY | 414.97 Thousand USD | -91.53% |
| 2003 Q4 | 103.79 Thousand USD | 15.93% |
| 2003 Q2 | 88.38 Thousand USD | -3.7% |
| 2003 Q1 | 91.77 Thousand USD | -36.83% |
| 2003 Q3 | 89.53 Thousand USD | 1.3% |
| 2002 Q1 | 126.21 Thousand USD | -5.0% |
| 2002 Q2 | 127.07 Thousand USD | 0.68% |
| 2002 Q3 | 4.5 Million USD | 3442.83% |
| 2002 Q4 | 145.28 Thousand USD | -96.77% |
| 2002 FY | 4.89 Million USD | 422.67% |
| 2001 Q1 | 147.1 Thousand USD | -70.79% |
| 2001 Q3 | 150.71 Thousand USD | 10.97% |
| 2001 Q2 | 135.82 Thousand USD | -7.67% |
| 2001 FY | 937.31 Thousand USD | -44.07% |
| 2001 Q4 | 132.86 Thousand USD | -11.85% |
| 2000 Q4 | 503.67 Thousand USD | -3.35% |
| 2000 Q2 | 241.43 Thousand USD | 101.36% |
| 2000 Q1 | -17.79 Million USD | -8872.22% |
| 2000 FY | 1.67 Million USD | 105.24% |
| 2000 Q3 | 521.13 Thousand USD | 115.85% |
| 1999 FY | 816.59 Thousand USD | -91.09% |
| 1999 Q4 | 202.8 Thousand USD | 0.0% |
| 1998 Q3 | 6.56 Million USD | 496.39% |
| 1998 FY | 9.16 Million USD | 7.4% |
| 1998 Q1 | 1 Million USD | 11.11% |
| 1998 Q2 | 1.1 Million USD | 10.0% |
| 1997 FY | 8.52 Million USD | 59.49% |
| 1997 Q4 | 900 Thousand USD | -86.42% |
| 1997 Q3 | 6.62 Million USD | 1225.78% |
| 1997 Q2 | 500 Thousand USD | -16.67% |
| 1997 Q1 | 600 Thousand USD | -33.33% |
| 1996 FY | 5.34 Million USD | -19.55% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q3 | -5.34 Million USD | 0.0% |
| 1996 Q4 | 900 Thousand USD | 116.83% |
| 1995 Q4 | - USD | 0.0% |
| 1995 FY | 6.64 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | 100.0% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | 100.0% |
| Innovation1 Biotech Inc. | 1.21 Million USD | 100.0% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | 100.0% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | 100.0% |